Fig. 6From: Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle EastProportion of patients free from disability progression according to EDSS score (FAS). DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; EOS, end of study; FAS, full analysis set Back to article page